Kate Jaycox Appointed to Help Lead Zofran Litigation

In December 2015, the Honorable F. Dennis Saylor IV appointed Robins Kaplan LLP principal Kate Jaycox to the Plaintiffs’ Steering Committee for In Re: Zofran (ondansetron) Products Liability Litigation, MDL 2657.  Judge Saylor was chosen to preside over the Zofran federal multi-district litigation (MDL) in October 2015.

Going forward, every claim filed in any federal court will automatically be transferred to the Zofran MDL in the District Court of Massachusetts, under the guidance of Judge Saylor. Ms. Jaycox is honored to help lead this litigation to try to obtain justice for the families and children affected by birth defects due to use of Zofran during pregnancy.  

Several scientific studies have linked Zofran use during pregnancy to birth defects. For example, a 2012 study found that women who took Zofran were twice as likely to have a child with cleft palate.1  An August 2013 study surveying 897,000+ births in Denmark found a two-fold increased risk of heart defects in children of women who took Zofran during pregnancy, a risk which led to an overall 30% increased risk of major malformation.2  

Robins Kaplan LLP is investigating cases in which a child was born with birth defects after the mother took Zofran during her first or early second trimester.  We are investigating claims involving heart defects, cleft palette, cleft lip, as well as other birth defects.  If you or someone you know has given birth to a child with a birth defect after taking Zofran during pregnancy and you wish to consult with a lawyer, please call us at 1-800-553-9910 or contact us.